•   
  •   

Health & Fitness Anti-viral drug remdesivir reduces risk of hospitalization by 87%

01:50  23 september  2021
01:50  23 september  2021 Source:   dailymail.co.uk

Ivermectin developer hopes pill could prevent Covid

  Ivermectin developer hopes pill could prevent Covid Merck & Co, which develops ivermectin, has being late-stage trials on the drug molnupiravir, which some believe could prevent the spread of viruses like COVID-19.Merck & Co partnered with Ridgeback Biotherapeutics to develop molnupiravir.

The antiviral remdesivir treatment reduced the risk of hospitalization among COVID-19 patients when administered soon after they were diagnosed, according to a new study. Researchers found that remdesivir cut hospitalization risk by 87 percent compared to a placebo that half of the study participants received. Some 562 patients, all deemed at high- risk from COVID-19, were enrolled in the trial. Gilead Sciences, which conducted the Phase 3 randomized, double-blind trial, stopped enrollment in April because the company struggled to find enough participants. But it continued to follow those

“As leaders in antiviral drug development, we welcome these findings and continue to invest in research of Veklury and novel oral antivirals to address the unmet need for effective and convenient therapies that can be administered at home.” On entering the body Veklury is transformed into the active metabolite remdesivir triphosphate, which is then incorporated into the viral RNA and stops replication of the virus within the host cell. No known variations have significantly altered the viral RNA polymerase. All known novel virus variants show mutations at different locations in the SARS-CoV-2

MailOnline logo © Provided by Daily Mail MailOnline logo

Remdesivir reduces the risk of hospitalization and medical visits due to COVID-19 in high-risk patients, new data suggest.

California-based Gilead Sciences Inc, the maker of the antiviral drug, published the results of its Phase III clinical trial on Wednesday.

Researchers found patients treated with remdesivir were 87 percent less likely to be hospitalized and 81 less likely to require a medical visit than those who were given a placebo.

The team says the findings shows that remdesivir, the only drug fully approved to treat severely ill coronavirus patients, can also be used for those who are at-high risk of becoming seriously ill - but are still early on in their infection.

Moderna Covid vaccine most effective against hospitalization at 93%

  Moderna Covid vaccine most effective against hospitalization at 93% A new CDC report found that the Moderna COVID-19 vaccine is 93% effective against hospitalization compared to 88% for the Pfizer vaccine and 71% for Johnson % Johnson.There are currently three immunizations authorized for use in the U.S.: Moderna, Pfizer-BioNTech and Johnson & Johnson/Janssen.

Remdesivir is a prodrug that is intended to allow intracellular delivery of GS-441524 monophosphate and subsequent biotransformation into GS-441524 triphosphate, a ribonucleotide analogue inhibitor of viral RNA polymerase.[19]. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class In the United States, remdesivir is indicated for use in adults and adolescents (aged twelve years and older with body weight at least 40 kilograms (88 lb)) for the treatment of COVID‑19 requiring hospitalization .[7] In November 2020, the FDA issued an emergency use authorization (EUA) for the

" Antiviral medications provide maximal benefit when used early in the disease course. Last summer, data from clinical trials demonstrated the benefit of remdesivir in patients hospitalized with COVID-19, even when not yet requiring oxygen. These latest data show remdesivir 's potential to help high- risk "We are seeing very high numbers of hospitalized patients as new COVID-19 infections surge, placing increased demands on already over-burdened healthcare systems. Remdesivir , also known as Veklury, is an effective antiviral for the treatment of hospitalized patients with COVID-19 and an

Researchers looked at 562 COVID-19 patients in a clinical trial who were at high-risk of developing severe illness and half were given remdesivir, the only drug approved by the FDA to treat seriously ill coronavirus patients. Pictured: A vial of remdesivir, April 2021 © Provided by Daily Mail Researchers looked at 562 COVID-19 patients in a clinical trial who were at high-risk of developing severe illness and half were given remdesivir, the only drug approved by the FDA to treat seriously ill coronavirus patients. Pictured: A vial of remdesivir, April 2021 chart: Patients treated with remdesivir were 87% less likely to be hospitalized and 81% likely to require a medical visit than those who were given a placebo. (above) © Provided by Daily Mail Patients treated with remdesivir were 87% less likely to be hospitalized and 81% likely to require a medical visit than those who were given a placebo. (above)

Remdesivir was developed Gilead to treat Ebola, the deadly fever that emerged in West Africa in 2014.

While it was unsuccessful in treating Ebola, the drug appears to interfere with the ability of the coronavirus to copy its genetic material.

In April 2020, the National Institutes of Health (NIH) released results from a study that found remdesivir helped patients recover 31 percent faster.

WHO recommends Regeneron's Covid antibody treatment

  WHO recommends Regeneron's Covid antibody treatment A panel of experts representing the WHO has recommended that high-risk COVID-19 patients receive Regeneron's monoclonal antibody treatment to boost their immune systems.Regeneron's treatment - which the U.S. Food & Drug Administration (FDA) authorized in the U.S. in November - includes two antibodies, called casirivimab and imdevimab, that can boost patients' immune systems.

Remdesivir has "little or no effect on mortality" for patients hospitalized with coronavirus and it doesn't seem to help Covid-19 patients recover any faster, either.

Remdesivir is seen at Eva Pharma facility in Cairo. (Reuters) - Gilead Sciences Inc said an analysis showed its antiviral remdesivir reduced mortality rates in hospitalized patients with COVID-19 and increased the likelihood of being discharged by day 28 after a five-day course of the treatment. The drugmaker said on Monday it analyzed data from 98,654 patients from three retrospective studies of the real-world treatment of hospitalized COVID-19 patients. Remdesivir achieved statistically significant 54% and 23% reduction in risk of mortality among the analyzed patients in two of the studies, the

This led to the U.S. Food and Drug Administration (FDA) issuing emergency use authorization for the drug the following month.


Video: World Alzheimer's Day: Raising awareness about neurodegenerative disease (France 24)

A few months later, in October 2020, the FDA fully approved the drug of the use in adults and in pediatric patients ages 12 to 17 who require hospitalization.

The new trial, however, shows that the treatment may also be effective in treating patients before they are hospitalized.

Researchers looked at 562 participants at high-risk of developing severe COVID-19, of whom half were given remdesivir and the other half a placebo.

After four weeks, 5.3 percent of the placebo group were hospitalized compared to 0.7 percent of the placebo group.

The team said that this suggests the medication reduces the risk of hospitalization by 87 percent.

Merck asks the FDA to authorize the first pill to treat COVID-19

  Merck asks the FDA to authorize the first pill to treat COVID-19 Merck & Co announced on Monday that it has applied for emergency use authorization with for its experimental COVID-19 pill to treat mild-to-moderate COVID-19 patients. The drug, called molnupiravir, stops the virus from making copies of itself, which prevents it from spreading throughout the body.Recent trial data have shown that it can halve the chances of death or being hospitalized for those most at risk of contracting a severe case of Covid.

Remdesivir (GS-5734), an inhibitor of the viral RNA-dependent, RNA polymerase with in vitro inhibitory activity against SARS-CoV-1 and the Middle East respiratory syndrome (MERS-CoV),5-8 was identified early as a promising therapeutic candidate for Covid-19 because of its ability to inhibit SARS-CoV-2 in Remdesivir has also received full or conditional approval in several other countries since that time. However, given high mortality despite the use of remdesivir , it is clear that treatment with an antiviral drug alone is not likely to be sufficient for all patients. Current strategies are evaluating remdesivir in

Remdesivir is an inhibitor of the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp), which is essential for viral replication. Remdesivir is an adenosine nucleotide prodrug that is metabolized to the pharmacologically active nucleoside triphosphate metabolite after being distributed into cells. Coronavirus disease 2019 (COVID-19): Treatment of COVID-19 in adult and pediatric patients (12 years of age and older weighing at least 40 kg) requiring hospitalization . Remdesivir should only be administered in a hospital or in a health care setting capable of providing acute care comparable to

Additionally, the trial looked at any patients who required medical visits due to COVID-19.

  Anti-viral drug remdesivir reduces risk of hospitalization by 87% © Provided by Daily Mail   Anti-viral drug remdesivir reduces risk of hospitalization by 87% © Provided by Daily Mail

By day 28, 8.3 percent of the placebo group had sought medical care in comparison with 1.6 percent of the treatment group.

Researchers say this means the drug reduces the risk of a medical visit by 81 percent.

'Antiviral medications provide maximal benefit when used early in the disease course,' Dr Robert Gottlieb, principal investigator at Baylor University Medical Center and Baylor Scott & White Research Institute, said in a statement.

'We are seeing very high numbers of hospitalized patients as new COVID-19 infections surge, placing increased demands on already over-burdened healthcare systems.

'Remdesivir, also known as Veklury, is an effective antiviral for the treatment of hospitalized patients with COVID-19 and an essential tool to help reduce disease progression.'

  Anti-viral drug remdesivir reduces risk of hospitalization by 87% © Provided by Daily Mail Read more

Merck ready to deliver 10 million doses of its Covid pill by years end .
Robert Davis, CEO of Merck, told CNBC on Thursday that his company is prepared to ship tens of millions of doses of the antiviral pill molnupiravir, pending regulatory approval.Robert Davis, CEO of the Kenilworth, New Jersey-based company, told CNBC on Thursday that the firm is ready to deploy massive shipments of the drug as soon as it gets the greenlight from the U.S. Food and Drug Administration (FDA).

usr: 1
This is interesting!